Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysine-specific demethylase 4B (KDM4B), also known as JMJD2B, is a member of the Jumonji C (JmjC) domain-containing family of histone demethylases. It specifically catalyzes the demethylation of di- and tri-methylated lysine 9 on histone H3 (H3K9me2/me3), thereby acting as a critical epigenetic regulator that relaxes chromatin structure to facilitate gene transcription, DNA replication, and DNA repair. KDM4B is frequently overexpressed in various malignancies, including breast, prostate, colorectal, and gastric cancers, as well as pediatric rhabdomyosarcoma and atypical teratoid/rhabdoid tumors (ATRT). In these contexts, it functions as an oncogene by co-activating key transcription factors like the estrogen receptor (ER), androgen receptor (AR), and the PAX3-FOXO1 fusion protein, thereby promoting cell proliferation, survival, and metastasis.
Beyond oncology, KDM4B has been implicated in driving host inflammatory responses and osteoclastogenesis in periodontal disease. Consequently, KDM4B is a highly attractive therapeutic target. Small-molecule inhibitors, such as the clinical-stage pan-KDM4 inhibitor zavondemstat (TACH101) and preclinical compounds like QC6352 and ML324, target KDM4B by competing with its co-factor alpha-ketoglutarate or chelating the catalytic Fe(II) ion in its active site. However, recent studies have revealed that some of these inhibitors, including zavondemstat and QC6352, also potently inhibit dihydroorotate dehydrogenase (DHODH), suggesting that their therapeutic efficacy and safety profiles may involve dual epigenetic and metabolic mechanisms.
Inhibition of the demethylase activity of KDM4B by competing with the co-factor alpha-ketoglutarate (2-oxoglutarate) and/or chelating the catalytic Fe(II) ion in the JmjC active site, thereby preventing the demethylation of histone H3 lysine 9 (H3K9me3/me2).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysine-specific demethylase 4B (KDM4B) (KDM4B).